## Bodybuilding Peptide Fat Loss Protocols with GLP-1 ### Cutting Phase Protocol For bodybuilders using GLP-1 peptides during a dedicated fat loss or cutting phase: | Week | Semaglutide | Tirzepatide | Retatrutide | |------|-------------|-------------|-------------| | 14 | 0.25 mg/week | 2.5 mg/week | 1 mg/week | | 58 | 0.5 mg/week | 5 mg/week | 2 mg/week | | 912 | 1.0 mg/week | 7.510 mg/week | 4 mg/week | | 1316 | 1.72.4 mg/week | 1015 mg/week | 812 mg/week | Gradual titration is essential to minimize gastrointestinal side effects that could interfere with training and nutrition for muscle building
For our application, classification models predict the known mGSH transporter SLC25A39 but not SLC25A40 as being highly probably related to mGSH metabolism in cancers
A graphical journey through iron metabolism, microRNAs, and hypoxia in ferroptosis
PLoS Pathog 6: e1001066
In South Africa, where obesity rates are on the rise, GLP1 medications such Ozempic, originally created for type 2 diabetes, have become a hot topic
These include: Nausea (very common, affecting up to 20% of patients) Diarrhoea (very common) Vomiting (common) Abdominal pain (common) Constipation (common) Dyspepsia (common) These gastrointestinal effects typically emerge during treatment initiation or dose escalation and often diminish over time as the body adapts to the medication